Wade Andrews

Special Counsel
Full contact info

Experience

Kura Oncology Announces Global Strategic Collaboration With Kyowa Kirin

November 20, 2024

Cooley advised clinical-stage biopharmaceutical company Kura Oncology (Nasdaq: KURA) on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia and other hematologic malignancies.

Read more

Related contacts

Charity Williams
Partner, San Diego
Dr. Chen Chen
Partner, Boston
Jonathan Kaufman
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Amanda Pacheco
Associate, Palo Alto
Howard Morse
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Charles Bair
Partner, San Diego
Andrew Epstein
Special Counsel, Seattle
Rachel Thorn
Partner, New York
Wade Andrews
Special Counsel, San Diego
María Álvarez Requejo Heredero
Associate, Brussels
Zhijing Yu
Associate, Singapore
Natasha Leskovsek
Of Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion

December 20, 2022

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

 

Read more

Related contacts

Barbara Borden
Senior Counsel, San Diego
Rama Padmanabhan
Partner, San Diego
Rowook Park
Partner, San Diego
Kelly Murata
Paralegal Specialist, San Francisco
Michael Tollini
Partner, Washington, DC
Todd Gluth
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Edmond Lay
Partner, San Diego
Peter Adams
Partner, San Diego
Dr. Fraser Brown
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Patrick Van Eecke
Partner, Brussels
David Fletcher
Partner, Washington, DC
Caroline Hobson
Partner, London
Alexander Israel
Partner in Charge – Brussels, Brussels
Christopher Kimball
Partner, Washington, DC
Mischi a Marca
Partner, San Francisco
Chadwick Mills
Partner, San Francisco
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
John Paul Oleksiuk
Partner, New York
Michelle Garcia Schulman
Partner, Reston
Lei Shen
Partner, Chicago
Charity Williams
Partner, San Diego
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Christine Graham
Special Counsel, London
Natasha Leskovsek
Of Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Stella Sarma
Special Counsel, Brussels
Matthew D. Silverman
Special Counsel, Santa Monica
Karen Tsai
Special Counsel, Washington, DC
Karun Ahuja
Special Counsel, Chicago
Wade Andrews
Special Counsel, San Diego
Ajay Athavale
Associate, San Francisco
Anna Caro
Associate, London
Umer Chaudhry
Associate, Washington, DC
Megan Drill
Associate, San Diego
Michael Fernando
Associate, London
Daniel Gillon
Associate, San Diego
Zack Gong
Associate, Shanghai
Ellie Seber
Partner, Santa Monica
Justin Kisner
Special Counsel, Palo Alto
Jessica Koffel
Special Counsel, Brussels
Allison Kutner
Associate, New York
Jan Lang
Associate, Brussels
Katie Adams
Associate, Reston
Dani Nazemian
Special Counsel, San Diego
Linh Nguyen
Associate, San Diego
Allison Wettstein O’Neill
Associate, San Diego
Alexandra Paterson
Associate, London
Addison Pierce
Partner, Chicago
Bartholomäus Regenhardt
Associate, Brussels
Grant Schweikert
Special Counsel, Washington, DC
Nathaniel Hearn Jr.
Associate, Chicago
Megan Browdie
Partner, Washington, DC

Related Practices & Industries

Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion

June 4, 2022

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Read more

Related contacts

Barbara Borden
Senior Counsel, San Diego
Rowook Park
Partner, San Diego
Charles Bair
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Alessandra Murata
Partner, Palo Alto
Ross Eberly
Partner, Santa Monica
Koji Fukumura
Partner, San Diego
Phil Mitchell
Partner, New York
David Navetta
Partner, Colorado
Todd Gluth
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Matthew D. Silverman
Special Counsel, Santa Monica
Stella Sarma
Special Counsel, Brussels
Christine Graham
Special Counsel, London
Megan Drill
Associate, San Diego
Heidi E. Wang
Associate, San Diego
Eileen Leman
Associate, Los Angeles
Daniel Gillon
Associate, San Diego
Wade Andrews
Special Counsel, San Diego
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Reneo Pharmaceuticals – $94 Million IPO

April 8, 2021

Cooley advised Reneo Pharmaceuticals on its $93.8 million initial public offering of 6,250,000 shares of common stock. Reneo Pharmaceuticals, whose securities now trade on the Nasdaq Global Market under the symbol RPHM, is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Partners Jason Kent and Kristin VanderPas led the Cooley team.

Related contacts

Jason Kent
Partner, New York
Kristin VanderPas
Partner, San Francisco
Wade Andrews
Special Counsel, San Diego

Related Practices & Industries

Equillium – $65.4 Million IPO

October 11, 2018

Cooley advised Equillium, Inc. on its $65.4 million initial public offering of 4,670,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 700,500 shares. Partners Tom Coll and Karen Anderson led the Cooley team advising Equillium.

Jefferies, Leerink Partners and Stifel Nicolaus & Company acted as joint book-running managers for the offering.

Equillium is a biotechnology company leveraging immunobiology to develop products for severe autoimmune and inflammatory disorders with a high unmet medical need. The company’s shares now trade on the Nasdaq Global Market under the symbol “EQ.”

Related contacts

Tom Coll
Partner, San Diego
Wade Andrews
Special Counsel, San Diego
Edmond Lay
Partner, San Diego

Related Practices & Industries

View more